Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers.

Autor: Ünçel M; Department of Pathology and Surgery, Tepecik Training and Research Hospital, İzmir, Turkey., Diniz G; Department of Pathology and Surgery, Tepecik Training and Research Hospital, İzmir, Turkey., Aköz G; Department of Pathology and Surgery, Tepecik Training and Research Hospital, İzmir, Turkey., Ekin ZY; Department of Pathology and Surgery, Tepecik Training and Research Hospital, İzmir, Turkey., Sayhan S; Department of Pathology and Surgery, Tepecik Training and Research Hospital, İzmir, Turkey., Yardım S; Department of Pathology and Surgery, Tepecik Training and Research Hospital, İzmir, Turkey., Salimoğlu S; Department of Pathology and Surgery, Tepecik Training and Research Hospital, İzmir, Turkey.
Jazyk: angličtina
Zdroj: European journal of breast health [Eur J Breast Health] 2019 Apr 01; Vol. 15 (2), pp. 125-129. Date of Electronic Publication: 2019 Apr 01 (Print Publication: 2019).
DOI: 10.5152/ejbh.2019.4677
Abstrakt: Objective: Breast cancer is the most common cancer among women worldwide. Adenine thymine-rich interactive domain 1A (ARIDIA) is a tumor suppressor gene involved in chromatin remodeling and it encodes the ARIDIA protein. Recent studies have shown the loss of ARIDIA protein expression in different carcinomas may have a prognostic significance. In the present study, we aimed to evaluate the interactions between ARIDIA loss and molecular subtypes of breast carcinomas.
Materials and Methods: ARIDIA expressions were studied in 292 formalin- fixed, paraffin- embedded breast carcinoma specimens and its association with different pathological and clinical parameters was evaluated.
Results: Loss of ARIDIA expression was detected in 123 cases. There was no statistically significant association between ARID-1A expression and molecular subtype of breast carcinomas (p=0.110) or HER2 amplification (p=0.909). Contrarily, there was a significant association between ARIDIA expression and presence of estrogen (p=0.047) or progesterone receptors (p=0.023). Besides a statistically significant relationship was found between loss of ARID1A, and the presence of both in situ component (p=0.016) and lymph node metastasis (p=0.001).
Conclusion: In this study, we have demonstrated that loss of ARID1A expression positively correlates with hormone receptor status as well as tumor aggressiveness.
Competing Interests: Conflict of Interest: The authors have no conflicts of interest to declare.
Databáze: MEDLINE
Externí odkaz: